EVOLUS, INC. Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
EVOLUS, INC. (EOLS) had Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net of $3.19 million as of 2025-03-31, per its 10-Q filed 2025-05-07.
Financial Statements › Notes › Debt › Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet · last filed 2025-05-07
- 2025-03-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $3.19M.
- 2024-12-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $3.49M.
- 2024-09-30: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $3.79M.
- 2024-06-30: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $4.08M.
| Period end | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net |
|---|---|
| 2025-03-31 | $3.19M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $3.49M 10-K · filed 2025-03-04 |
| 2024-09-30 | $3.79M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $4.08M 10-Q · filed 2024-07-31 |
| 2024-03-31 | $4.36M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $4.64M 10-K · filed 2024-03-07 |
| 2023-09-30 | $4.91M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $5.17M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $2.95M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $3.12M 10-K · filed 2023-03-08 |
| 2022-09-30 | $3.29M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $3.46M 10-Q · filed 2022-08-02 |
| 2022-03-31 | $3.62M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $3.78M 10-K · filed 2022-03-03 |
| 2020-06-30 | $835.00K 10-Q · filed 2020-08-10 |
| 2020-03-31 | $1.16M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $1.49M 10-K · filed 2020-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |